Welcome to our dedicated page for Biodexa Pharmaceuticals plc news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals plc stock.
Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company whose news flow centers on the clinical and regulatory progress of its lead programs eRapa, tolimidone and MTX110. Company announcements and SEC Form 6-K filings describe ongoing activity in familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes and rare or orphan brain cancers.
Investors following BDRX news can expect regular updates on the Serenta Phase 3 trial of eRapa in FAP, including milestones such as enrollment of the first patients, activation of new clinical sites in the United States and Europe, and approval of a Clinical Trial Application by the European Medicines Agency. Releases also provide context on the FAP disease burden and the lack of approved non-surgical treatment options, which frame the rationale for eRapa’s development.
Biodexa’s news stream also covers pipeline developments beyond FAP. The company reports progress in a Phase 2 study of eRapa in NMIBC, a Phase 2a investigator-initiated trial of tolimidone in type 1 diabetes, and early-stage studies of MTX110 in aggressive brain cancers. Operational updates, such as orphan drug designations, Fast Track designation, and collaborations with organizations like Emtora Biosciences, LumaBridge and Precision for Medicine, feature prominently.
In addition, BDRX news includes corporate and financing events such as equity line agreements, warrant transactions, ADR ratio changes and public offerings of ADS Units and pre-funded units, as detailed in Form 6-K filings. Governance and leadership changes, including board appointments and executive role updates, are also disclosed through press releases. For readers tracking BDRX, this news page offers a consolidated view of clinical milestones, regulatory steps and capital markets activity related to Biodexa’s development programs.
Biodexa Pharmaceuticals (Nasdaq: BDRX) held a General Meeting on May 2, 2025, where two ordinary resolutions received majority votes of 62% and 61%. However, a crucial special resolution (Resolution 3) failed to pass, receiving 71% of votes when it needed 75%. Since Resolution 1 was dependent on Resolution 3's approval, it also failed despite its majority vote. The failed Resolution 3 was aimed at reducing the nominal value of shares to provide more flexibility in future fundraising efforts. The company's Chairman, Dr. Stephen Parker, indicated that alternative proposals will be presented in the future.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has announced a General Meeting scheduled for May 2, 2025, at 13:00 BST at their Cardiff offices. The meeting will address three key resolutions:
1. Subdivision of each issued ordinary share (£0.00005) into one ordinary share (£0.000001) and 49 D deferred shares (£0.000001)
2. Approval of directors' remuneration policy
3. Adoption of new articles of association
The primary objective of these resolutions is to reduce the par value of ordinary shares, enabling the company to issue shares above par value. The company emphasizes that these changes will not affect the number of outstanding ordinary shares or American Depositary Shares.
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has released its audited preliminary financial results for the fiscal year ending December 31, 2024. The company, which positions itself as an acquisition-focused clinical stage biopharmaceutical company, is developing a pipeline of innovative products targeting diseases with unmet medical needs.
Biodexa Pharmaceuticals (NASDAQ:BDRX) is advancing towards initiating a Phase 3 trial for eRapa, its proprietary encapsulated rapamycin formulation for treating familial adenomatous polyposis (FAP). The company recently achieved key milestones including FDA Fast Track designation and a successful Type C meeting.
The Phase 3 study will be a double-blind placebo-controlled trial involving approximately 168 high-risk FAP patients across 30 clinical sites in the U.S. and Europe. The trial is substantially funded with a $17 million grant from the Cancer Prevention Research Institute of Texas, matched by $8.5 million from Biodexa.
The company's Phase 2 trial demonstrated promising results, with cohort 2 showing an 89% non-progression rate and 29% median reduction in polyp burden at 12 months. Biodexa has appointed LumaBridge and Precision for Medicine as CROs for the U.S. and European components respectively.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced successful results from its Type C meeting with the FDA regarding the Phase 3 protocol for eRapa in familial adenomatous polyposis (FAP). The meeting focused on statistical planning, safety database, and composite endpoint discussions for the Phase 3 study.
The upcoming Phase 3 trial will be a double-blind placebo-controlled study involving 168 patients, with a 2:1 drug/placebo randomization ratio, conducted across approximately 30 clinical sites in the US and Europe. The study is substantially funded by a $17.0 million CPRIT grant and an $8.5 million Company match, which has been placed in escrow.
This development follows successful Phase 2 data presentations at Digestive Disease Week (May 2024) and InSight Barcelona (June 2024). LumaBridge will manage the US component, while Precision for Medicine will oversee the European segment.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has appointed Precision for Medicine, as the clinical research organization (CRO) for the European component of its upcoming Phase 3 study of eRapa in Familial Adenomatous Polyposis (FAP). The U.S. component will be managed by LumaBridge in San Antonio, Texas.
The Phase 3 registrational study is designed as a double-blind placebo-controlled trial involving 168 patients, with a 2:1 drug/placebo randomization ratio. The study will be conducted across approximately 30 clinical sites in the US and Europe, with initiation planned for next quarter.
Precision, specializing in rare diseases, brings over 20 years of experience with 333 clinical trials in rare diseases and employs more than 700 team members across 11 European locations.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has received allowance for U.S. patent application No. 17/391.495, titled 'Oral Rapamycin Nanoparticle Preparations and Use' for its eRapa technology. The patent, exclusively licensed from Rapamycin Holdings (d/b/a Emtora Biosciences) in April 2024, will issue on March 4, 2025, and is expected to expire in March 2034.
The company plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter. The FDA has already granted orphan drug designation for eRapa in FAP, providing seven years of market exclusivity upon approval in the US. This new patent adds an additional layer of protection for the novel drug formulation as Biodexa explores additional indications.
Biodexa Pharmaceuticals (Nasdaq: BDRX), a clinical stage biopharmaceutical company, has announced its upcoming presentation at the Emerging Growth Conference on February 19, 2025. The company's CEO/CFO, Stephen Stamp, will deliver a live, interactive presentation at 09:40 AM Eastern time for 30 minutes.
The event offers shareholders and the investment community an opportunity to interact with Mr. Stamp in real-time. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the live session. For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
Registration is required for attendance and updates through the provided webcast link. Biodexa focuses on developing innovative products for diseases with unmet medical needs.
Biodexa Pharmaceuticals (NASDAQ:BDRX) has received FDA Fast Track status for eRapa, its drug treating familial adenomatous polyposis (FAP), following positive Phase 2 results and Orphan Drug designation. The Phase 2 trial showed promising results with a 17% median decrease in overall polyp burden and 75% non-progression rate. Notably, cohort 2 demonstrated an 89% non-progression rate and 29% median reduction in polyp burden at 12 months.
FAP is an inherited condition affecting 1 in 5,000-10,000 people in the U.S. and 1 in 11,300-37,600 in Europe, leading to a nearly 100% lifetime risk of colorectal cancer. Currently, there are no approved therapeutic options, with surgery being the standard treatment. The upcoming Phase 3 study will be double-blind placebo-controlled, recruiting approximately 168 high-risk FAP patients.